| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -410.00 | 1.32M | 2.24M | 23.90M | 60.88M | 55.24M |
| Gross Profit | -3.27M | -3.47M | -1.51M | 20.61M | 59.22M | 55.24M |
| EBITDA | -33.92M | -28.99M | -38.13M | -15.12M | -15.20M | 21.14M |
| Net Income | -37.06M | -34.10M | -42.19M | -18.74M | -17.14M | 20.12M |
Balance Sheet | ||||||
| Total Assets | 30.13M | 44.20M | 83.94M | 50.90M | 79.37M | 56.54M |
| Cash, Cash Equivalents and Short-Term Investments | 5.71M | 20.76M | 56.57M | 15.05M | 33.21M | 12.61M |
| Total Debt | 6.42M | 4.67M | 5.91M | 5.93M | 8.52M | 8.13M |
| Total Liabilities | 18.11M | 18.23M | 26.64M | 19.85M | 40.82M | 17.53M |
| Stockholders Equity | 12.02M | 25.97M | 57.30M | 31.06M | 38.55M | 39.01M |
Cash Flow | ||||||
| Free Cash Flow | -38.26M | -34.63M | -25.32M | -7.19M | -7.19M | -2.73M |
| Operating Cash Flow | -38.11M | -34.29M | -25.12M | 3.76M | 3.76M | 10.00M |
| Investing Cash Flow | 18.05M | -11.96M | -152.70K | -10.94M | -10.94M | -12.72M |
| Financing Cash Flow | -805.00K | -1.17M | 66.77M | 1.05M | 34.12M | 8.98M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $31.55M | -0.76 | -127.48% | ― | -95.87% | 35.25% | |
43 Neutral | $20.58M | -1.05 | -63.84% | ― | ― | 12.95% | |
40 Underperform | $13.90M | ― | -67.47% | ― | ― | 9.63% | |
36 Underperform | $24.62M | -0.36 | -104.07% | ― | ― | 1.66% | |
35 Underperform | $23.06M | ― | -66.12% | ― | 154.52% | 47.84% | |
31 Underperform | $19.83M | -0.30 | -183.72% | ― | ― | 20.28% |
On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from the Board of Directors of SAB Biotherapeutics, Inc., reducing the Board’s size from 11 to nine members. This change was in line with an agreement with RA Capital Healthcare Fund, L.P., following a private placement of securities in July 2025. The resignations were not due to any disagreements with the company, and the Board expressed gratitude for their service.
The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
On September 26, 2025, SAB Biotherapeutics held a special meeting where stockholders approved amendments to the company’s 2021 Omnibus Equity Incentive Plan, significantly increasing the number of shares available for participants. Additionally, stockholders approved the potential issuance of shares exceeding 19.99% of the company’s outstanding stock upon conversion of Series B Convertible Preferred Stock, which may be considered a ‘change of control’ under Nasdaq rules.
The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. In its latest earnings report, SAB Biotherapeutics disclosed a net loss of $15.3 million for the first half of 2025, compared to a $12.4 million loss in the same period last year, with no revenue generated during this time. The company’s operating expenses were primarily driven by research and development costs, which totaled $14.7 million, and general and administrative expenses of $5.9 million. Despite the financial losses, the company successfully raised approximately $175 million through a private placement offering to fund its ongoing research and development activities, including the Phase 2b SAFEGUARD study of its lead candidate, SAB-142. Looking ahead, SAB Biotherapeutics anticipates continued financial challenges as it progresses its product candidates through development and regulatory approval processes, with management actively seeking additional funding to support its long-term strategic goals.